| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Molecular and Cellular Biology, June 2008, p. 3804-3816, Vol. 28, No. 11
0270-7306/08/$08.00+0 doi:10.1128/MCB.00709-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Lise Madsen,1,3,4,
Lone Møller Pedersen,1
Philip Hallenborg,1
Hanne Hagland,3
Kristin Viste,3
Stein Ove Døskeland,3 and
Karsten Kristiansen1*
Department of Biochemistry and Molecular Biology, University of Southern Denmark, DK-5230 Odense M, Denmark,1 BioLigands, International Science Park Odense, DK-5230 Odense M, Denmark,2 Department of Biomedicine, University of Bergen, N-5009 Bergen, Norway,3 National Institute of Nutrition and Seafood Research, 5817 Bergen, Norway4
Received 23 April 2007/ Returned for modification 23 July 2007/ Accepted 17 March 2008
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Elevation of cellular cAMP concentration has been associated with crucial events in the early program of differentiation, such as suppression of Wnt10b (5) and Sp1 (64) and induction of CCAAT/enhancer-binding protein β (C/EBPβ) (10, 29, 70). Moreover, the transcriptional activity of peroxisome proliferator-activated receptor
(PPAR
) is regulated synergistically by ligands and cAMP (32). In addition, cAMP has been implicated in the production of endogenous PPAR
ligand(s) occurring during the initial stages of differentiation (46, 67). The cAMP-responsive element-binding protein (CREB) is a central transcriptional activator of the adipocyte differentiation program. Activated CREB induces expression of C/EBPβ, triggering expression of a number of transcription factors, including C/EBP
and PPAR
(16, 64-66, 70, 72). Indeed, forced expression of constitutively active CREB can induce adipogenesis, whereas expression of a dominant-negative form of CREB blocks differentiation (56). The importance of CREB is underscored by the finding that adipocyte differentiation of CREB-deficient mouse embryo fibroblast is impaired (72) and that small interfering RNA-mediated depletion of CREB and the closely related activating transcription factor 1 (ATF1) blocks adipocyte differentiation (26). CREB was initially characterized as a cAMP target whose transcriptional activity was stimulated by cAMP-dependent protein kinase (protein kinase A [PKA])-catalyzed phosphorylation on serine 133 (28), but insulin (Ins) signaling may also activate CREB in 3T3-L1 cells through Ser-133 phosphorylation via the extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathway (40).
While cAMP signaling via PKA has been investigated for decades, the complexity of cAMP signaling via interplay between PKA and the exchange proteins directly activated by cAMP (Epac1 and Epac2) is only beginning to be understood. Epac1 and Epac2 function as guanine nucleotide exchange factors (GEFs) for the Ras-like small GTPases Rap1 and Rap2 (6), and possibly Rit (60), and several cAMP-dependent processes are now believed to be modulated by Epac. Epac may mediate cAMP-dependent exocytosis (36, 37, 52) and integrin-dependent cell adhesion (17, 24, 54). Whereas Epac and PKA can exert opposing effects in regulating downstream targets such as protein kinase B (PKB) (49), they act synergistically to promote PC-12 cell differentiation, as judged by neurite extension (15).
The present work was undertaken to determine if Epac had any role in cAMP-stimulated adipocyte differentiation of 3T3-L1 preadipocytes and, if so, to dissect the contributions of Epac and PKA. We demonstrate that cAMP stimulated adipocyte differentiation through the concerted action of PKA and Epac/Rap. A similar finding was made for cAMP-stimulated adipocyte differentiation of MEFs. While stimulation of PKA activity was not required for the increased phosphorylation of CREB during the initiation of adipocyte differentiation, it was important for the suppression of Rho/Rho-kinase activity. Inhibition of Rho-kinase activity in 3T3-L1 preadipocytes decreased Ins/IGF-1 signaling, but concomitant activation of Epac restored Ins/IGF-1 sensitivity. Accordingly, adipocyte differentiation was still Epac dependent when Rho-kinase was inhibited, whereas PKA activity was dispensable under such conditions. This interplay between PKA-, Epac-, and Rho-kinase-mediated processes provides novel insight into regulatory circuits controlling the initiation of adipocyte differentiation and provides a new example of how cAMP can use both PKA and Epac to achieve an appropriate cellular response.
| MATERIALS AND METHODS |
|---|
|
|
|---|
DN, and pJim was a kind gift from Reidun Kopperud. Cell culture and differentiation. 3T3-L1 cells were cultured to confluence in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% calf serum. Two-days-postconfluent (designated day 0) cells were induced to differentiate with DMEM supplemented with 10% fetal bovine serum (FBS) and 1 µM dexamethasone (Dex) (Sigma). One microgram per milliliter Ins (Sigma) or IGF-1 (Sigma), 0.5 mM IBMX (Sigma), 100 µM 8-para-chloro-phenylthio-cAMP (8-CPT-cAMP), 200 µM 8-(4-chlorophenylthio)-2'-O-methyl-cAMP (8-pCPT-2'-O-Me-cAMP) (Biolog), 100 µM N6-monobutyryl-cAMP (6-MB-cAMP) (Biolog), and/or 100 µM N6-benzoyl-cAMP (6-Bnz-cAMP) was included as indicated in the figure legends. After 48 h, the media were replaced with DMEM supplemented with 10% FBS and 1 µg/ml Ins or IGF-1 as indicated in the figure legends. The cells were subsequently refed every 48 h with DMEM supplemented with 10% fetal bovine serum. When included, H-89 (10 µM) (Biomol), sc-3536 (10 µM), (Santa Cruz), and Rp-8-Br-cAMPS/Rp-cAMPS (100 µM) (Biolog) were present from day 0 to day 2. The preparation of MEFs has been described previously (44). MEFs were grown in AmnioMax basal medium (Life Technologies, Inc.) supplemented with 7.5% FBS, 7.5% AmnioMax-C100 supplement, and 2 mM glutamine and were induced to differentiate as 3T3-L1 cells. Staining of lipid by oil red O was performed as described previously (32).
Retroviral transduction.
Phoenix-Eco cells were plated at 30 to 40% confluence in DMEM supplemented with 10% FBS. Next day, the cells were transfected using a standard calcium phosphate method by adding 10 µg retroviral expression vector (pJim-RI
DN, pLXSN-dnEpac1, pLXSN-RhoA-N19, pBABE-Rap1N17, or the empty retroviral vectors) and 15 µg pBSK (Stratagene) to a total of 25 µg DNA per 9-cm dish. Two days posttransfection, the virus-containing media were collected by centrifugation and immediately used to infect 30 to 40% confluent 3T3-L1 cells by mixing viral supernatant 1:1 with DMEM supplemented with 10% calf serum. Polybrene (Sigma) was added to a final concentration. of 7 µg/ml. After 24 h, the transduced cells were split and subjected to selection (400 µg/ml hygromycin B [Calbiochem] or 3 µg/ml puromycin). After approximately 4 days, the selected clones were pooled and replated for differentiation.
Real-time RT-PCR.
Total RNA was purified from cells using Trizol, and cDNA was synthesized as described earlier (46) and quantified by real-time quantitative PCR (qPCR) using the ABI PRISM 7700 sequence detection system (Applied Biosystems). Each PCR mixture contained, in a final volume of 25 µl, 1 µl of first-strand cDNA, 12.5 µl of 2x Sybr green PCR master mix, and 5 pmol of each primer. All reactions were performed using the following cycling conditions: 50°C for 2 min and 95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. PCR was carried out in 96-well plates and in duplicate. Primers for real-time reverse transcription-PCR (RT-PCR) were designed using Primer Express 2.0 (Applied Biosystems). Target gene mRNA expression was normalized to transcription factor IIB (TFIIB) or TATA-binding protein (TBP) mRNA expression, and the relative amounts of all mRNAs were calculated. The following primers were used (upstream and downstream, respectively): Epac1, 5'-GGGACTCCGCTGGACACC and 5'-CGGCCAGAGCAGCAATGCCG; Epac2, 5'-CAATCGGATTCTGAGGGACG and 5'-CATTTAAAACCGAATCTG; C/EBP
, 5'-CAAGAACAGCAACGAGTACCG and 5'-GTCACTGGTCAACTCCAGCAC; aP2, 5'-CTGGGCGTGGAATTCGAT and 5'-GCTCTTCACCTTCCTGTCGTCT; PPAR
2, 5'-ACAGCAAATCTCTGTTTTATGC and 5'-TGCTGGAGAAATCAACTGTGG; LXR
, 5'-GAGTTGTGGAAGACAGAACCTCAA and 5'-GGGCATCCTGGCTTCCTC; and TBP, 5'-ACCCTTCACCAATGACTCCTATG and 5'-ATGATGACGGCAGCAAATCGC.
Western blotting.
Obtaining whole-cell extracts, electrophoresis, blotting, visualization, and stripping of membranes were performed as described previously (31). The primary antibodies used were obtained from the following sources: Cell Signaling Technology, mouse anti phospho-ERK1/2 (Thr-202/Tyr-204), rabbit anti-ERK1/2, rabbit anti-phospho-PKB (Ser-473), rabbit anti-PKB, mouse anti-CREB, mouse anti-phospho-myosin light chain (MLC [Ser-19]), and rabbit anti-MLC; Upstate, mouse anti-phospho-CREB (Ser-133); Cayman Chemical, rabbit anti FABP4/aP2; and Santa Cruz, rabbit anti-PPAR
and rabbit anti-TFIIB. The secondary antibodies were horseradish peroxidase-conjugated antimouse or antirabbit antibodies obtained from DAKO.
Determination of PKA activity in cell lysates.
Cells were incubated for 15 min with various agents supposed to modulate their cAMP level or PKA activity, washed in ice-cold phosphate-buffered saline, and lysed in 0.5 ml of 50 mM potassium phosphate buffer (pH 7.0) with 1 mM EGTA, 0.3 mM EDTA, 2 mM 1,4-dithioerythriol (DTE), 0.15% Triton X-100, and Complete protease inhibitor cocktail (Roche). Lysates were snap-frozen in liquid nitrogen and thawed immediately before assay of kinase activity, which was performed essentially as described by Ekanger et al. (22). Briefly, incubations were for 5 to 10 min at 30°C in 15 mM HEPES-NaOH, 50 mM potassium phosphate, 10 mM magnesium acetate, 0.5 mM EGTA, 100 µM [
-32P]ATP, and 70 µM kemptide (LRRASLG) substrate. Some incubations contained cAMP, cAMP analogs, or kinase inhibitors (see the relevant figure legend for details). The blank value was determined by incubating in the presence of 100 nM of the inhibitor peptide from the heat-stable PKA inhibitor.
Other assays. Rap1 and Rho activity were measured using the Rap1 activation assay kit (no. 17-321; Upstate) and the Rho activity kit (no. 17-294; Upstate).
Statistical analysis. Statistical evaluation of the data was performed using Student t test. A P value of <0.05 was considered to be significant. n denotes the number of independent assays or experiments.
| RESULTS |
|---|
|
|
|---|
|
|
|
To support the results obtained by pharmacological activation of Epac1 and PKA, 3T3-L1 cells were transduced with a retroviral vector expressing a dominant-negative form of Epac1 or the empty vector and tested for their ability to undergo cAMP-stimulated adipose conversion. Control cells transduced with the empty vector differentiated when both Epac and PKA were activated by 8-pCPT-2'-O-Me-cAMP and 6-MB-cAMP in combination. In contrast, in cells expressing the dominant-negative form of Epac1, the majority of the cells remained fibroblast-like and were not stained by oil red O (Fig. 4A). Furthermore, the induction of PPAR
and adipocyte lipid-binding protein (aP2) was severely blunted in the cells transduced with dnEpac1 (Fig. 4B). Knockdown of Epac1 expression by lentivirus-mediated expression of anti-Epac1 short hairpin RNA similarly blunted differentiation of 3T3-L1 preadipocytes (data not shown).
|
|
2 and aP2 (Fig. 4E). Collectively, these findings indicate that cAMP-dependent activation of the Epac1/Rap1 pathway is required for adipocyte differentiation.
The data in the preceding paragraphs suggested that active PKA was necessary, but not sufficient, for cAMP-stimulation of adipogenesis. The role of PKA was ascertained by the demonstration that the PKA-specific inhibitory cAMP analogs of the equatorial diastereoisomer of adenosine-3',5'-cyclic monophosphorothioate (Rp-8-Br-cAMPS/Rp-cAMPS) (15) counteracted 3T3-L1 cell differentiation (Fig. 5 A) and that differentiation was blocked by forced expression of dominant-negative RI
(Fig. 5C), which, like the Rp-cAMPS analogs, significantly decreased the PKA activity in 3T3-L1 cell extracts (data not shown). In contrast, the widely used, but nonspecific, PKA inhibitor H89 failed to abrogate cAMP-stimulated adipogenesis (Fig. 5A). This suggested that PKA could act by inhibiting an additional kinase targeted by H89. In this way H89 would make PKA superfluous for differentiation. H89 is a potent inhibitor of Rho-kinases (42), which therefore would be a prime candidate for the putative kinase inactivated downstream of PKA; the more so as inhibition of Rho-kinase constitutes a crucial step for initiation of adipocyte differentiation (51). Since the Rho-kinase is stimulated by GTP-Rho, an obvious mechanism of PKA-induced inhibition of Rho-kinase would be to convert Rho-GTP to the inactive Rho-GDP form. In fact, activation of PKA alone or in combination with activation of Epac reduced the level of Rho-GTP to undetectable levels, whereas activation of Epac alone had no effect, and furthermore, activation of PKA by 6-MB-cAMP decreased phosphorylation of the Rho-kinase substrate MLC (Fig. 5B). To further substantiate the notion that PKA activation stimulated adipogenesis via downregulation of a Rho/Rho-kinase-dependent pathway, we examined whether pharmacological inhibition of Rho-kinase was sufficient to restore adipogenesis of 3T3-L1 cells expressing the dominant-negative form of the RI
subunit. As predicted, addition of the Rho-kinase inhibitor sc-3536 restored the differentiation of cells expressing the dominant-negative RI
subunit as determined by oil red O staining (Fig. 5C) and expression of the adipocyte marker proteins PPAR
and aP2 (Fig. 5D). Based on these findings, we conclude that activation of PKA is dispensable for efficient adipocyte differentiation in the presence of Dex, high levels of Ins, and IBMX, provided that the Rho-kinase is inhibited.
|
and induced for 15 min with Dex, Ins, and IBMX, in the absence or presence of the selective PKA inhibitor Rp-cAMPS or the MEK inhibitor U0126. Cell extracts were analyzed for CREB and MAPK phosphorylation by Western blotting. Figure 6C demonstrates that phosphorylation of CREB and ERK1/2 was induced also when the PKA inhibitor was present and in cells expressing the dominant-negative form of RI
. In contrast, the MEK inhibitor almost completely prevented the increased phosphorylation of not only ERK1/2, but also CREB. In vitro kinase assays demonstrated that the MEK kinase inhibitor (and the Rho-kinase inhibitor) did not inhibit PKA, whereas H89 potently inhibited PKA (Fig. 6D). Finally, we demonstrated that expression of a canonical CREB-responsive gene was induced by Dex, Ins, and IBMX in the presence of the PKA inhibitor Rp-cAMPS, but not in the presence of the MEK inhibitor (Fig. 6E). CREB has been shown to play a pivotal role during initiation of adipocyte differentiation, at least in part by regulating the expression of C/EBPβ (72), although alternative routes for induction of C/EBPβ also seem to exist (26). It is well established that phosphorylation of Ser-133 is necessary, but not sufficient, for CREB-mediated transactivation and that additional PKA-dependent processes may be needed for transcriptional activation (8). However, taken together all experiments described above argue against PKA being directly involved in CREB phosphorylation and activation. Rather, the activation of CREB and the ensuing induction of C/EBPβ expression appear to depend on Ins/IGF-1 signaling. Therefore, we propose that Rho-kinase and not CREB is a central target for PKA activation during the onset of the adipocyte differentiation program.
Ins/IGF-1 signaling is crucial for adipogenesis, so it is puzzling that inhibition of Rho-kinase is essential for induction of adipocyte differentiation since inhibition of Rho-kinase also impairs Ins signaling in adipocytes (27). We reasoned that activation of Epac might overcome the negative effect of Rho-kinase inhibition on Ins/IGF-1 signaling. In fact, Epac activation has been shown to potentiate Ins signaling in muscle cells (7). The supraphysiological concentration of Ins used in the standard Dex-Ins-IBMX differentiation protocols mimics IGF-1, the main adipogenic inducer, by interacting with the IGF-1 receptor (59, 61). To demonstrate that inhibition of Rho-kinase impaired IGF-1/Ins signaling in 3T3-L1 preadipocytes, the effect of the Rho-kinase-inhibitor sc-3536 was studied in cells stimulated with increasing concentrations of IGF-1 in the presence or absence of the Epac activator 8-pCPT-2'-O-Me-cAMP. The fetal calf serum used in the present experiments contained 10 nM IGF-1 (data not shown). Hence, the final concentration of IGF-1 in the medium containing 10% serum was 1 nM. Phosphorylation of PKB was determined as a marker of IGF-1 signaling. We found that the Rho-kinase inhibitor decreased IGF-1-dependent PKB phosphorylation. Importantly, activation of Epac enhanced PKB phosphorylation and restored the IGF-1-dependent PKB phosphorylation in the presence of the Rho-kinase inhibitor (Fig. 7). Thus, Epac activation stimulated IGF-1 signaling whether the Rho-kinase was inhibited or not.
|
|
| DISCUSSION |
|---|
|
|
|---|
|
The first clue to the importance of Rho-kinase inhibition for the adipogenic action of PKA came through the observation that the PKA/Rho-kinase inhibitor H89 could substitute for PKA in supporting differentiation (Fig. 5A) (38, 51, 53). In the present report, we show in addition that a more specific Rho-kinase inhibitor as well as dominant-negative RhoA also could substitute for PKA and that PKA activation decreased active Rho-GTP and abolished the phosphorylation of the Rho-kinase target MLC. We propose therefore that the major role of PKA in promoting adipocyte differentiation may be through inhibition of Rho/Rho-kinase.
Mesenchymal determination and terminal differentiation along the adipocyte, myocyte, and osteocyte lineages are controlled by cell shape and cytoskeletal tension (34, 48, 50, 62), converging on regulation of Rho and Rho-kinase activity (48, 51, 63). We propose that PKA can decrease cell tension by converting RhoA to the inactive GTP-free form, which leads to relaxation of microfilaments, in part via inhibition of Rho-kinase-catalyzed phosphorylation of MLC. This relaxation of cell tension will lead to further inhibition of Rho. There are several known mechanisms for PKA-mediated inhibition of Rho. One is inactivating phosphorylation of RhoA by PKA (21, 41), a second is AKAP-Lbc phosphorylation by anchored PKA followed by recruitment of 14-3-3 and decreased Rho-GEF activity (20), and a third is PKA-catalyzed phosphorylation of G
13 with consequent inhibition of Rho activation (1). Results presented here and previously published data show that repression of Rho activity is a point of convergence for adipogenesis-promoting signals. Sordella and coworkers have demonstrated that IGF-1-dependent phosphorylation of p190-B RhoGAP induces a translocation of p190-B RhoGAP to lipid rafts, leading to a down-regulation of Rho activity (63) Conversely, forced expression of the selective Rho-GEF, GEFT, prevents 3T3-L1 preadipocyte differentiation (9). Recently, it was furthermore shown that inhibition or genetic ablation of Rho-kinase (ROCK-II/ROK
) but not ROCK-I/ROKβ promoted adipocyte differentiation (51).
Epac was discovered as a cAMP-stimulated Rap activator (19), but has also been reported to act independently of Rap to stimulate the Jun-kinase (18) or activate R-ras (33, 39). In the 3T3-L1 model of adipocyte differentiation, we found that activation of Epac1 increases Rap1-GTP and that its stimulation of adipocyte differentiation was counteracted by dnRap1. This suggests that Epac1 acted to promote adipogenesis via activation of Rap1. A further clue to what role Epac1 might have in adipogenesis was provided by our observation that Epac1 activation could overcome the paradoxical negative effect of inhibition of Rho-kinase on IGF-1/Ins signaling. This may be related to the observations that inhibition of Rho-kinase activity impairs Ins signaling in cultured adipocytes and myocytes and causes Ins resistance with impaired glucose uptake in skeletal muscle of mice (27). Rho-kinase-dependent stimulation of Ins signaling was found to be associated with phosphorylation of serine residues 632 and 635 of Ins receptor substrate 1 (IRS-1) (27). On the other hand, Rho-kinase can inhibit Ins signaling through phosphorylation of serine 612 of IRS-1 (2, 3, 63). Thus, to achieve optimal insulin/IGF-1 signaling the activity of the Rho-kinase must be regulated within a very narrow window, a situation reminiscent of the p120 catenin-dependent regulation of adhesion junctions, where both inhibition of Rho activity and strong activation of Rho can block the formation of junctions (69). Thus, under conditions with elevated levels of cAMP resulting in PKA-dependent inhibition of Rho activity, effective Ins/IGF-1 signaling might dependent on a compensatory sensitizing effect by the Epac branch of the cAMP effector machinery.
Using phosphorylation of PKB as a measure of IGF-1 signaling, we demonstrate that Rho-kinase inhibition impaired and Epac1 activation enhanced IGF-1-dependent activation of PKB and, furthermore, we show that activation of Epac1 fully restored or even enhanced PKB activation in the presence of a Rho-kinase inhibitor. Similarly, activation of Epac1 potentiated Ins-dependent activation of PKB in skeletal muscle (7).
We speculate that activation of Rap may be one common feature of Epac and IGF-1 signaling, explaining at least in part the ability of Epac activation to compensate for limiting levels of Ins/IGF-1. Thus, the adaptor protein c-Crk, which recruits C3G, a GEF for Rap1, has been shown to be required as an early signaling mediator of IGF-1-induced adipocyte differentiation of 3T3-L1 preadipocytes (35). C3G is able to activate Rap1 in NIH 3T3 cells (43), and hence, it is conceivable that the same is true for 3T3-L1 adipocytes. How Epac-Rap1 activation sensitizes Ins/IGF-1 signaling in preadipocytes remains to be elucidated. In muscle, it was shown that activation of Epac promoted Ins-stimulated recruitment of phosphatidylinositol 3-kinase (PI3-K) to signaling complexes. However, no interaction between the p85 subunit of the PI3-K and Rap1 analogous to the interaction between cdc42 and p85 (68) could be detected (7), and the molecular basis for the increased PI3-K recruitment remains to be established.
The synergistic action of Ins/IGF-1 and cAMP signaling during initiation of adipocyte differentiation is remarkable and contrasts the normal interplay between insulin and cAMP signaling in liver, muscle, and mature adipocytes. In mature adipocytes, stimulation of β-adrenergic receptors increases cAMP levels, leading to PKA activation and stimulation of lipolysis by PKA-mediated phosphorylation of hormone-sensitive lipase and perilipin. In this setting, Ins disrupts the coupling between the β2-adrenergic receptor and PKA presumably through modulation of AKAP scaffolding proteins (71). Similarly, the channeling of cAMP signaling via Epac also seems to vary between preadipocytes and adipocytes. In preadipocytes, our results show that activation of Epac increases Ins/IGF-1 signaling and PKB activation, whereas activation of Epac by 8-pCPT-2'-O-Me-cAMP in primary rat adipocytes decreases Ins-dependent activation of PKB (73). Thus, cAMP-dependent signals appear to follow different routes in preadipocytes and mature adipocytes. In addition, the marked differences in the number of receptors for Ins and IGF-1, respectively, in preadipocytes and mature adipocytes (61) coupled with the increased expression of small G-proteins such as TC10
, which is recruited to CAP-Cbl-C3G complexes in lipid rafts in response to Ins and required for Ins non-PI3-K-dependent translocation of Glut4 (11, 13), may well in a competitive manner affect Epac-independent Rap activation. Further deciphering of the cross talk between cAMP-dependent signaling and Ins/IGF-1 signaling promises novel avenues for insight into the complex signaling governing the transition from preadipocytes and adipocytes as well as metabolic regulation in mature adipocytes.
| ACKNOWLEDGMENTS |
|---|
This work was carried out as a part of the research program of the Danish Obesity Research Centre (DanORC). DanORC is supported by The Danish Council for Strategic Research (grant no. 2101-06-0005). This work was in addition supported by the Danish Natural Science Research Council, the Norwegian Research Council, and the NOVO Foundation.
L.M. and K.K. are founders and members of the board of BioLigands ApS, and R.K.P. is an employee of BioLigands ApS.
| FOOTNOTES |
|---|
Published ahead of print on 7 April 2008. ![]()
R.K.P. and L.M. contributed equally to this work. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Begum, N., O. A. Sandu, and N. Duddy. 2002. Negative regulation of rho signaling by insulin and its impact on actin on cytoskeleton organization in vascular smooth muscle cells: role of nitric oxide and cyclic guanosine monophosphate signaling pathways. Diabetes 51:2256-2263.[CrossRef][Medline]
3. Begum, N., O. A. Sandu, M. Ito, S. M. Lohmann, and A. Smolenski. 2002. Active Rho kinase (ROK-alpha) associates with insulin receptor substrate-1 and inhibits insulin signaling in vascular smooth muscle cells. J. Biol. Chem. 277:6214-6222.
4. Belmonte, N., B. W. Phillips, F. Massiera, P. Villageois, B. Wdziekonski, P. Saint-Marc, J. Nichols, J. Aubert, K. Saeki, A. Yuo, S. Narumiya, G. Ailhaud, and C. Dani. 2001. Activation of extracellular signal-regulated kinases and CREB/ATF-1 mediate the expression of CCAAT/enhancer binding proteins β and -
in preadipocytes. Mol. Endocrinol. 15:2037-2049.
5. Bennett, C. N., S. E. Ross, K. A. Longo, L. Bajnok, N. Hemati, K. W. Johnson, S. D. Harrison, and O. A. MacDougald. 2002. Regulation of Wnt signaling during adipogenesis. J. Biol. Chem. 277:30998-31004.
6. Bos, J. L. 2006. Epac proteins: multi-purpose cAMP targets. Trends Biochem. Sci. 31:680-686.[CrossRef][Medline]
7. Brennesvik, E. O., C. Ktori, J. Ruzzin, E. Jebens, P. R. Shepherd, and J. Jensen. 2005. Adrenaline potentiates insulin-stimulated PKB activation via cAMP and Epac: implications for cross talk between insulin and adrenaline. Cell. Signal. 17:1551-1559.[CrossRef][Medline]
8. Brindle, P., T. Nakajima, and M. Montminy. 1995. Multiple protein kinase A-regulated events are required for transcriptional induction by cAMP. Proc. Natl. Acad. Sci. USA 92:10521-10525.
9. Bryan, B. A., D. C. Mitchell, L. Zhao, W. Ma, L. J. Stafford, B.-B. Teng, and M. Liu. 2005. Modulation of muscle regeneration, myogenesis, and adipogenesis by the Rho family guanine nucleotide exchange factor GEFT. Mol. Cell. Biol. 25:11089-11101.
10. Cao, Z., R. Umek, and S. McKnight. 1991. Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells. Genes Dev. 5:1538-1552.
11. Chang, L., S. H. Chiang, and A. R. Saltiel. 2007. TC10alpha is required for insulin-stimulated glucose uptake in adipocytes. Endocrinology 148:27-33.
12. Chawla, S., and H. Bading. 2001. CREB/CBP and SRE-interacting transcriptional regulators are fast on-off switches: duration of calcium transients specifies the magnitude of transcriptional responses. J. Neurochem. 79:849-858.[CrossRef][Medline]
13. Chiang, S. H., C. A. Baumann, M. Kanzaki, D. C. Thurmond, R. T. Watson, C. L. Neudauer, I. G. Macara, J. E. Pessin, and A. R. Saltiel. 2001. Insulin-stimulated GLUT4 translocation requires the CAP-dependent activation of TC10. Nature 410:944-948.[CrossRef][Medline]
14. Christensen, A. E., and S. O. Doskeland. 2003. Cyclic nucleotide analogs, p. 549-554. In R. Bradshaw and E. Dennis (ed.), Handbook of cell signaling, vol. 2. Academic Press, San Diego, CA.[CrossRef]
15. Christensen, A. E., F. Selheim, J. de Rooij, S. Dremier, F. Schwede, K. K. Dao, A. Martinez, C. Maenhaut, J. L. Bos, H. G. Genieser, and S. O. Doskeland. 2003. cAMP analog mapping of Epac1 and cAMP kinase: discriminating analogs demonstrate that Epac and cAMP kinase act synergistically to promote PC-12 cell neurite extension. J. Biol. Chem. 278:35394-35402.
16. Christy, R. J., K. H. Kaestner, D. E. Geiman, and M. D. Lane. 1991. CCAAT/enhancer binding protein gene promoter: binding of nuclear factors during differentiation of 3T3-L1 preadipocytes. Proc. Natl. Acad. Sci. USA 88:2593-2597.
17. Cullere, X., S. K. Shaw, L. Andersson, J. Hirahashi, F. W. Luscinskas, and T. N. Mayadas. 2004. Regulation of vascular endothelial barrier function by Epac, a cAMP activated exchange factor for Rap GTPase. Blood 105:1950-1955.[CrossRef][Medline]
18. De Jesus, M. L., M. B. Stope, P. A. O. Weernink, Y. Mahlke, C. Borgermann, V. N. Ananaba, C. Rimmbach, D. Rosskopf, M. C. Michel, K. H. Jakobs, and M. Schmidt. 2006. Cyclic AMP-dependent and Epac-mediated activation of R-Ras by G protein-coupled receptors leads to phospholipase D stimulation. J. Biol. Chem. 281:21837-21847.
19. de Rooij, J., F. J. T. Zwartkruis, M. H. G. Verheijen, R. H. Cool, S. M. B. Nijman, A. Wittinghofer, and J. L. Bos. 1998. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396:474-477.[CrossRef][Medline]
20. Diviani, D., L. Abuin, S. Cotecca, and L. Pansier. 2004. Anchoring of both PKA and 14-3-3 inhibits the Rho-GEF activity of the AKAP-Lbc signaling complex. EMBO J. 23:2811-2820.[CrossRef][Medline]
21. Dong, J. M., T. Leung, E. Manser, and L. Lim. 1998. cAMP-induced morphological changes are counteracted by the activated RhoA small GTPase and the Rho kinase ROKalpha. J. Biol. Chem. 273:22554-22562.
22. Ekanger, R., and S. O. Døskeland. 1988. Use of antibody-sepharose columns to study hormonal activation of cAMP-dependent protein kinase isozymes. Methods Enzymol. 159:97-104.[Medline]
23. Enserink, J. M., A. E. Christensen, J. de Rooij, M. van Triest, F. Schwede, H. G. Genieser, S. O. Doskeland, J. L. Blank, and J. L. Bos. 2002. A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK. Nat. Cell Biol. 4:901-906.[CrossRef][Medline]
24. Enserink, J. M., L. S. Price, T. Methi, M. Mahic, A. Sonnenberg, J. L. Bos, and K. Tasken. 2004. The cAMP-Epac-Rap1 pathway regulates cell spreading and cell adhesion to laminin-5 through the
3β1 integrin but not the
6β4 integrin. J. Biol. Chem. 279:44889-44896.
25. Farmer, S. R. 2006. Transcriptional control of adipocyte formation. Cell Metab. 4:263-273.[CrossRef][Medline]
26. Fox, K. E., D. M. Fankell, P. F. Erickson, S. M. Majka, J. T. Crossno, Jr., and D. J. Klemm. 2006. Depletion of cAMP-response element binding protein/ATF1 inhibits adipogenic conversion of 3T3-L1 cells ectopically expressing CCAAT/enhancer binding protein (C/EBP) alpha, C/EBP beta or PPAR gamma 2. J. Biol. Chem. 281:40341-40353.
27. Furukawa, N., P. Ongusaha, W. J. Jahng, K. Araki, C. S. Choi, H. J. Kim, Y. H. Lee, K. Kaibuchi, B. B. Kahn, H. Masuzaki, J. K. Kim, S. W. Lee, and Y. B. Kim. 2005. Role of Rho-kinase in regulation of insulin action and glucose homeostasis. Cell Metab. 2:119-129.[CrossRef][Medline]
28. Gonzalez, G., and M. Montminy. 1989. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 59:675-680.[CrossRef][Medline]
29. Hamm, J. K., B. H. Park, and S. R. Farmer. 2001. A role for C/EBPbeta in regulating peroxisome proliferator-activated receptor gamma activity during adipogenesis in 3T3-L1 preadipocytes. J. Biol. Chem. 276:18464-18471.
30. Hansen, J. B., and K. Kristiansen. 2006. Regulatory circuits controlling white versus brown adipocyte differentiation. Biochem. J. 398:153-168.[CrossRef][Medline]
31. Hansen, J. B., R. K. Petersen, C. Jorgensen, and K. Kristiansen. 2002. Deregulated MAPK activity prevents adipocyte differentiation of fibroblasts lacking the retinoblastoma protein. J. Biol. Chem. 277:26335-26339.
32. Hansen, J. B., H. Zhang, T. H. Rasmussen, R. K. Petersen, E. N. Flindt, and K. Kristiansen. 2001. Peroxisome proliferator-activated receptor delta (PPARdelta)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling. J. Biol. Chem. 276:3175-3182.
33. Hochbaum, D., T. Tanos, F. Ribeiro-Neto, D. Altschuler, and O. A. Coso. 2003. Activation of JNK by Epac is independent of its activity as a Rap guanine nucleotide exchanger. J. Biol. Chem. 278:33738-33746.
34. Jakkaraju, S., Z. Zhe, D. Pan, R. Choudhury, and L. Schuger. 2005. TIPs are tension-responsive proteins involved in myogenic versus adipogenic differentiation. Dev. Cell 9:39-49.[CrossRef][Medline]
35. Jin, S., B. Zhai, Z. Qiu, J. Wu, M. D. Lane, and K. Liao. 2000. c-Crk, a substrate of the insulin-like growth factor-1 receptor tyrosine kinase, function as an early signal mediator in the adipocyte differentiation process. J. Biol. Chem. 275:34344-34352.
36. Kang, G., O. G. Chepurny, and G. G. Holz. 2001. cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic beta-cells. J. Physiol. (London) 536:375-385.
37. Kang, G., J. W. Joseph, O. G. Chepurny, M. Monaco, M. B. Wheeler, J. L. Bos, F. Schwede, H. G. Genieser, and G. G. Holz. 2003. Epac-selective cAMP analog 8-pCPT-2'-O-Me-cAMP as a stimulus for Ca2+-induced Ca2+ release and exocytosis in pancreatic β-cells. J. Biol. Chem. 278:8279-8285.
38. Kato, Y., N. Ozaki, T. Yamada, Y. Miura, and Y. Oiso. 2007. H-89 potentiates adipogenesis in 3T3-L1 cells by activating insulin signaling independently of protein kinase A. Life Sci. 80:476-483.[CrossRef][Medline]
39. Keiper, M., M. B. Stope, D. Szatkowski, A. Bohm, K. Tysack, F. vom Dorp, O. Saur, P. A. Oude Weernink, S. Evellin, K. H. Jakobs, and M. Schmidt. 2004. Epac- and Ca2+-controlled activation of Ras and extracellular signal-regulated kinases by Gs-coupled receptors. J. Biol. Chem. 279:46497-46508.
40. Klemm, D. J., W. J. Roesler, T. Boras, L. A. Colton, K. Felder, and J. E. B. Reusch. 1998. Insulin stimulates cAMP-response element binding protein activity in HepG2 and 3T3-L1 cell lines. J. Biol. Chem. 273:917-923.
41. Lang, P., F. Gesbert, M. Delespine-Carmagnat, R. Stancou, M. Pouchelet, and J. Bertoglio. 1996. Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes. EMBO J. 15:510-519.[Medline]
42. Leemhuis, J., S. Boutillier, G. Schmidt, and D. K. Meyer. 2002. The protein kinase A inhibitor H89 acts on cell morphology by inhibiting Rho kinase. J. Pharmacol. Exp. Ther. 300:1000-1007.
43. Ling, L., T. Zhu, and P. E. Lobie. 2003. Src-CrkII-C3G-dependent activation of Rap1 switches growth hormone-stimulated p44/42 MAP kinase and JNK/SAPK activities. J. Biol. Chem. 278:27301-27311.
44. Lukas, J., J. Bartkova, M. Rohde, M. Strauss, and J. Bartek. 1995. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol. Cell. Biol. 15:2600-2611.[Abstract]
45. MacDougald, O. A., and M. D. Lane. 1995. Transcriptional regulation of gene expression during adipocyte differentiation. Annu. Rev. Biochem. 64:345-373.[CrossRef][Medline]
46. Madsen, L., R. K. Petersen, M. B. Sørensen, C. Jørgensen, P. Hallenborg, L. Pridal, J. Fleckner, E.-Z. Amri, P. Krieg, G. Furstenberger, R. K. Berge, and K. Kristiansen. 2003. Adipocyte differentiation of 3T3-L1 preadipocytes is dependent on lipoxygenase activity during the initial stages of the differentiation process. Biochem. J. 375:539-549.[CrossRef][Medline]
47. Mayr, B. M., G. Canettieri, and M. R. Montminy. 2001. Distinct effects of cAMP and mitogenic signals on CREB-binding protein recruitment impart specificity to target gene activation via CREB. Proc. Natl. Acad. Sci. USA 98:10936-10941.
48. McBeath, R., D. M. Pirone, C. M. Nelson, K. Bhadriraju, and C. S. Chen. 2004. Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev. Cell 6:483-495.[CrossRef][Medline]
49. Mei, F. C., J. Qiao, O. M. Tsygankova, J. L. Meinkoth, L. A. Quilliam, and X. Cheng. 2002. Differential signaling of cyclic AMP. J. Biol. Chem. 277:11497-11504.
50. Meyers, V. E., M. Zayzafoon, J. T. Douglas, and J. M. McDonald. 2005. RhoA and cytoskeletal disruption mediate reduced osteoblastogenesis and enhanced adipogenesis of human mesenchymal stem cells in modeled microgravity. J. Bone Miner. Res. 20:1858-1866.[CrossRef][Medline]
51. Noguchi, M., K. Hosoda, J. Fujikura, M. Fujimoto, H. Iwakura, T. Tomita, T. Ishii, N. Arai, M. Hirata, K. Ebihara, H. Masuzaki, H. Itoh, S. Narumiya, and K. Nakao. 2007. Genetic and pharmacological inhibition of Rho-associated kinase II enhances adipogenesis. J. Biol. Chem. 282:29574-29583.
52. Ozaki, N., T. Shibasaki, Y. Kashima, T. Miki, K. Takahashi, H. Ueno, Y. Sunaga, H. Yano, Y. Matsuura, T. Iwanaga, Y. Takai, and S. Seino. 2000. cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat. Cell Biol. 2:805-811.[CrossRef][Medline]
53. Petersen, R. K., C. Jorgensen, A. C. Rustan, L. Froyland, K. Muller-Decker, G. Furstenberger, R. K. Berge, K. Kristiansen, and L. Madsen. 2003. Arachidonic acid-dependent inhibition of adipocyte differentiation requires PKA activity and is associated with sustained expression of cyclooxygenases. J. Lipid Res. 44:2320-2330.
54. Rangarajan, S., J. M. Enserink, H. B. Kuiperij, J. de Rooij, L. S. Price, F. Schwede, and J. L. Bos. 2003. Cyclic AMP induces integrin-mediated cell adhesion through Epac and Rap1 upon stimulation of the β2-adrenergic receptor. J. Cell Biol. 160:487-493.
55. Reedquist, K. A., E. Ross, E. A. Koop, R. M. Wolthuis, F. J. Zwartkruis, Y. van Kooyk, M. Salmon, C. D. Buckley, and J. L. Bos. 2000. The small GTPase, Rap1, mediates CD31-induced integrin adhension. J. Cell Biol. 148:1151-1158.
56. Reusch, J. E. B., L. A. Colton, and D. J. Klemm. 2000. CREB activation induces adipogenesis in 3T3-L1 cells. Mol. Cell. Biol. 20:1008-1020.
57. Reusch, J. E. B., and D. J. Klemm. 2002. Inhibition of cAMP-response element-binding protein activity decreases protein kinase B/Akt expression in 3T3-L1 adipocytes and induces apoptosis. J. Biol. Chem. 277:1426-1432.
58. Rosen, E. D., and O. A. MacDougald. 2006. Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell Biol. 7:885-896.[CrossRef][Medline]
59. Schmidt, W., G. Poll-Jordan, and G. Loffler. 1990. Adipose conversion of 3T3-L1 cells in a serum-free culture system depends on epidermal growth factor, insulin-like growth factor I, corticosterone, and cyclic AMP. J. Biol. Chem. 265:15489-15495.
60. Shi, G.-X., H. Rehmann, and D. A. Andres. 2006. A novel cyclic AMP-dependent Epac-Rit signaling pathway contributes to PACAP38-mediated neuronal differentiation. Mol. Cell. Biol. 26:9136-9147.
61. Smith, P. J., L. S. Wise, R. Berkowitz, C. Wan, and C. S. Rubin. 1988. Insulin-like growth factor-I is an essential regulator of the differentiation of 3T3-L1 adipocytes. J. Biol. Chem. 263:9402-9408.
62. Sordella, R., M. Classon, K. Hu, SF. Matheson, M. Brouns, B. Fine, L. Zhang, S. Takase, Y. Yamada, and J. Settleman. 2002. Modulation of CREB activity by the Rho GTPase regulates cell and organism size during mouse embryonic development. Dev. Cell 2:553-565.[CrossRef][Medline]
63. Sordella, R., W. Jiang, G. C. Chen, M. Curto, and J. Settleman. 2003. Modulation of Rho GTPase signaling